Edasalonexent is primarily investigated for its potential therapeutic applications in the treatment of Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration and weakness. It functions as an inhibitor of NF-κB, a signaling pathway involved in inflammation and muscle damage. By blocking this pathway, edasalonexent aims to slow disease progression, reduce inflammation, and preserve muscle function. Its application is focused on providing a disease-modifying treatment option for patients, particularly in pediatric cases, to improve quality of life and delay the need for more invasive interventions like corticosteroids. Clinical trials have explored its efficacy and safety, with the goal of offering a novel approach to managing DMD.